Tesamorelin

Investigated uses

• HIV-associated lipodystrophy; other metabolic/liver uses have been investigated but are not the catalog product’s approved indication.

Mechanism and hypotheses

• Tesamorelin is a growth-hormone-releasing-hormone analogue that binds pituitary GHRH receptors, increasing endogenous pulsatile growth hormone and downstream IGF-1.
• Hypothesized: Use for generalized weight loss, bodybuilding, anti-aging or recovery is not an established labeled mechanism-to-benefit relationship.

Human evidence

• Two 26-week randomized trials in adults with HIV lipodystrophy showed greater reduction in visceral adipose tissue than placebo. Limitations: Narrow population and product-specific formulation; not a general weight-loss treatment.

Safety highlights

• Injection-site reactions, arthralgia, myalgia, edema, hypersensitivity and glucose intolerance are label-recognized concerns.
• Risks include malignancy-related concerns from IGF-1 elevation, severe hypersensitivity and glucose intolerance/diabetes.

Regulatory context

Egrifta WR is FDA-approved for a narrow HIV-lipodystrophy indication; vendor tesamorelin vials are not established as Egrifta WR.